
Blood-based biomarker tests may revolutionize colorectal cancer screening, potentially replacing colonoscopies in the future.


coremsg

If colon cancer blood tests eventually win FDA approval and Medicare reimbursement, their use could become more widespread. But first this approach needs to match up against the current standard.

CRC Blood Tests: A Future Without Screening Colonoscopies?

blood-based-biomarker-tests-for-colorectal-cancer-screening


Blood-Based Biomarker Tests for Colorectal Cancer Screening


title_rewrite


Starting colorectal cancer screening at age 50 is recommended by the American College of Physicians.


The guidance contradicts recommendations from other groups that lowered the starting age to 45.

ACP Sticks With 50 as Age to Start CRC Screening

acp-recommends-starting-crc-screening-at-age-50


ACP Recommends Starting CRC Screening at Age 50



Blood-based screening for colorectal cancer is not as effective or cost-effective as established methods like colonoscopy.


Blood-based screening for CRC may be better than no screening at all, but it can&#039;t replace colonoscopy as the gold standard, according to two new modeling studies and an expert consensus commentary.

Blood-Based Screening for CRC Promising but Lacks Efficacy

blood-based-screening-for-colorectal-cancer-effectiveness-and-limitations


Blood-Based Screening for Colorectal Cancer: Effectiveness and Limitations



Blood tests show promise for colorectal cancer screening, but colonoscopy remains the gold standard.


The test had relatively high sensitivity in an average-risk population, raising hopes that it could help increase screening rates among patients who decline stool tests or colonoscopies.

Blood Test Has High Accuracy for Detecting CRC

blood-test-accuracy-for-detecting-colorectal-cancer


Blood Test Accuracy for Detecting Colorectal Cancer



Next-generation mt-sDNA test shows higher sensitivity but lower specificity compared to FIT for CRC screening.


A next-generation multitarget stool DNA test for colorectal cancer screening had higher sensitivity but lower specificity than a currently available FIT, according to the large prospective BLUE-C study.

CRC: Next-Generation mt-sDNA Test Beats FIT for Sensitivity

next-generation-mt-sdna-test-vs-fit-for-crc-screening


Next-Generation mt-sDNA Test vs. FIT for CRC Screening
